Loading stock data…
PRQR
$1.55-0.02 (-1.27%)
Market ClosedLast close May 1
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ProQR Therapeutics N.V. in the Healthcare sector is trading at $1.55. The stock is currently near its 52-week low of $1.33, remaining 23.3% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why PRQR maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.55
Potential Upside
5%
Whystock Fair Value$1.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$184.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-85.44%
Volume
Today's trading volume
462,722
Recent News
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
ProQR Therapeutics (NASDAQ:PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA editing program AX-0810, a next-generation follow-on candidate (AX-0811), and the addition of two pro
April 2026 Penny Stock Highlights
Over the last 7 days, the U.S. market has risen by 1.9%, contributing to a 24% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In such a thriving market, identifying stocks with solid financial foundations and growth potential is key for investors looking to capitalize on emerging opportunities. While penny stocks may seem like an outdated concept, they continue to offer access to smaller or newer companies that can provide both affordability...
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks
U.S. stocks pulled back on Friday, with the S&P 500 slipping 1.67%, as investors grew more cautious amid rising geopolitical tensions tied to the ongoing Iran conflict and the potential for higher oil prices to keep inflation elevated. Periods of uncertainty and market pullbacks, however, can also create opportunities to buy stocks at more attractive valuations. That’s a view shared by Oppenheimer’s chief investment strategist, John Stoltzfus, who sees room for optimism despite the recent volati
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings. The consensus price target of $9.44 implies a 448.56% upside, reflecting growing optimism about the company’s RNA […]